<DOC>
	<DOCNO>NCT02296918</DOCNO>
	<brief_summary>To evaluate safety preliminary efficacy acalabrutinib combination obinutuzumab 2 separate cohort patient .</brief_summary>
	<brief_title>Acalabrutinib Combination With Obinutuzumab Relapsed/Refractory Untreated CLL/SLL/PLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Patients diagnosis intermediate high risk CLL ( variant immunophenotype ) , SLL , BPLL IWCLL 2008 criterion ( 48 ) : Previously receive least one therapy disease . Previously untreated disease 65 year old OR 65 year old refuse ineligible chemoimmunotherapy All patient must satisfy one follow criterion active disease require therapy : Evidence marrow failure manifest development worsen anemia thrombocytopenia Massive ( ≥ 6 cm costal margin ) , progressive symptomatic splenomegaly Massive node ( ≥ 10 cm ) progressive symptomatic lymphadenopathy Constitutional symptom , include follow : Unintentional weight loss 10 % within 6 month Significant fatigue limit activity Fevers ≥100.5 degrees F 2 week without evidence infection Night sweat &gt; 1 month without evidence infection Patients history Richter 's transformation eligible evidence CLL , &lt; 10 % large cell bone marrow . ECOG performance status ≤ 2 Life expectancy &lt; 2 year would confound assessment toxicity study Must ≥ 18 year age Subject must complete CLL therapy ≥ 4 week prior first study dose . Any lifethreatening illness , medical condition , organ dysfunction , investigator 's opinion , could compromise patient ' safety , interfere absorption metabolism acalabrutinib , put study outcome undue risk . Female subject pregnant breastfeeding . Subjects active cardiovascular disease medically control myocardial infarction past 6 month . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction Major surgery within 4 week first dose study drug . History stroke intracranial hemorrhage within 6 month first dose study drug . Subjects human immunodeficiency virus ( HIV ) active infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) uncontrolled active systemic infection Requires treatment longacting proton pump inhibitor ( eg , omeprazole , esomeprazole , lansoprazole , dexlansoprazole , rabeprazole , pantoprazole )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>PLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
	<keyword>ACP-196</keyword>
	<keyword>acalabrutinib</keyword>
</DOC>